Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene Gets $15M Credit Facility to Fund Cancer Monitoring Tech Development, Commercialization

NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

The San Diego-based firm will use the capital to support development and commercialization of its urine-based cell-free oncogene mutation cancer monitoring technology.

Trovagene said it expects to report holding roughly $35 million in cash and cash equivalents for the second fiscal quarter, which ended on June 30. It reported $22.9 million in cash holdings at the end of the first quarter.

"We continue to advance our proprietary cancer monitoring platform and the application of our technology in clinical settings," Trovagene CFO Stephen Zaniboni said in a statement. "Recent progress includes clinical study results presented at ASCO 2014 and a reference in clinical consensus guidelines for the treatment of certain histiocytic disorders associated with BRAF V600E mutations."

Earlier this week, Trovagene said it partnered with Northwestern University's Robert H. Lurie Comprehensive Care Center and Northwestern Medicine Developmental Therapeutics Institute to assess the clinical utility of its oncogene-based disease management technology for monitoring patients during treatment and to measure outcomes.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.